Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Taltz and Zepbound combo sustains superior psoriasis and arthritis improvements at 52 weeks vs Taltz alone
LLY
$1,171.00
-$1.86 -0.16%

Taltz and Zepbound combo sustains superior psoriasis and arthritis improvements at 52 weeks vs Taltz alone

Company Fundamentals
31 Aug 2026
PRNewsWire
View Source
Bullish
pluang ai news

Eli Lilly's Phase 3b trials show that combining Taltz (ixekizumab) and Zepbound (tirzepatide) maintains or improves psoriasis and psoriatic arthritis outcomes at 52 weeks compared to Taltz alone in patients with obesity. The combo also sustains benefits in systemic inflammation and metabolic health, addressing both immune and metabolic aspects of these chronic diseases. No new safety concerns were reported, supporting a comprehensive treatment approach for patients with psoriatic disease and obesity. Detailed results will be shared in future medical meetings and publications.

More News (LLY)

Employer coverage for GLP-1 weight-loss drugs drops but Eli Lilly's sales keep soaring.

Employer coverage for GLP-1 weight-loss drugs drops but Eli Lilly's sales keep soaring.

Employer insurance coverage for GLP-1 weight-loss drugs in the U.S. fell from 72% in 2025 to 60% in 2026, signaling cost concerns among employers. Despite this, Eli Lilly's revenue surged 47.7% in Q2 2026, driven by strong sales of Zepbound and Mounj...

Market News
Neutral
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App